Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma

This study has been withdrawn prior to enrollment.
Celgene Corporation
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: August 10, 2010
Last updated: September 24, 2015
Last verified: September 2015
The purpose of this study is to see if a treatment with Lenalidomide, which is a pill given by mouth for 7.5 months (30 weeks total), can delay the growth of lymphoma or shrink the lymphoma. Lenalidomide is a pill that has been approved by the Food and Drug Administration (FDA). It is used to treat some forms of cancer-like illnesses (myelodysplastic syndrome (MDS)and in combination with dexamethasone for patients with multiple myeloma (MM) who have received at least 1 prior therapy. MDS and MM are cancers of the blood). This drug works by stimulating the body's immune system and by reducing the blood supply to cancer cells. Cancer cells need blood to live and grow. In this study, the drug is considered a new or experimental drug because we are learning how it works against your form of lymphoma.

Condition Intervention Phase
Follicular Lymphoma
Drug: lenalidomide
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma

Resource links provided by NLM:

Further study details as provided by Memorial Sloan Kettering Cancer Center:

Primary Outcome Measures:
  • Response rate (CR + PR). [ Time Frame: 2 years ]
    The primary objective of this study is to evaluate lenalidomide in previously untreated patients with advanced stage follicular lymphoma who do not require active lymphoma therapy.

Secondary Outcome Measures:
  • Response rate (CR + PR) and time to disease progression [ Time Frame: 2 years ]
    according to FLIPI score. The Follicular Lymphoma International Prognostic Index (FLIPI)

  • Immune monitoring and analysis of signal transduction in the lymph node. [ Time Frame: 2 years ]
  • Immune monitoring and analysis of signal transduction in the blood. [ Time Frame: 2 years ]

Enrollment: 0
Study Start Date: August 2010
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: lenalidomide
Eligible patients for this clinical trial will be treated for 6 cycles with lenalidomide at 15 mg daily by mouth on Days1-21 of 28 day cycle, preceded by an escalating schema for safety (5mg daily for 2 weeks; 10 mg daily for 2 weeks; and 15 mg daily for 2 weeks) and then a one week rest).
Drug: lenalidomide

Patient enrollment FNA of palpable lymph node prior to escalation phase

Escalation phase of Lenalidomide:

Lenalidomide 5 mg daily PO x 14 days Lenalidomide 10 mg daily PO x 14 days Lenalidomide 15 mg daily PO x 14 days Week of rest FNA of palpable lymph node prior to treatment phase

Treatment phase of Lenalidomide:

15 mg daily PO days 1-21 out of a 28 day cycle Repeat x 6 cycles


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed diagnosis of follicular lymphoma: grades I, II, or IIIA, (as defined in the WHO classification3) as reviewed by a hematopathologist at Memorial Hospital
  • No prior treatment for lymphoma permitted.
  • Measurable or evaluable disease is permitted; at least one peripheral site amenable to FNAs
  • Laboratory test results within these ranges
  • Absolute neutrophil count ≥ 2000
  • Platelet count ≥ 150,000
  • Creatinine clearance of ≥ 60 mL/min (may be actual or calculated by Cockroft-Gault formula
  • Total bilirubin 1.5 x ULN
  • AST (SGOT) and ALT (SGPT) ≤ 3 x ULN. Karnofsky performance status > 70%
  • The patient may not have a previous history of radiation therapy.
  • Patient or guardian must be able to sign voluntary written consent.
  • Male or female patients 18 years of age or greater.
  • Females of childbearing potential (FCBP)† must have a negative serum pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods (Appendix B), and also Appendix C: Education and Counseling Guidance Document.
  • Able to take aspirin (81 mg, if not already on aspirin) daily as prophylactic anticoagulation (Patients intolerant to ASA may use low molecular weight heparin). Although not recommended as prophylactic anti-coagulation, warfin may be used with clode monitoring of INR.

Exclusion Criteria:

  • Histologic diagnosis of follicular grade 3B or aggressive non-Hodgkin's lymphoma.
  • Histologic evidence of transformation from low grade/indolent NHL to aggressive NHL.
  • PET uptake in any of the involved sites greater than 12 (suggesting histologic transformation).
  • Regional lymphoma (peripheral stages I and II) eligible for involved field irradiation.Staging fulfills criteria for no initial treatment according to GELF criteria2 for advanced stage disease (not peripheral stage I and II amenable to involved field irradiation) . None of the following should be present:

    1. A nodal or extranodal mass with a diameter of >7 cm,
    2. Involvement of at least three nodal sites [each with a diameter of >3 cm],
    3. Systemic symptoms,
    4. Symptomatic splenomegaly, or
    5. Ureteral compression.
  • Patients with a known history of HIV, Hepatitis B or C seropositivity.
  • Patients with stool positive for H. Pylori (these patients are eligible for protocol 07-038).
  • Evidence of laboratory TLS by Cairo-Bishop Definition of Tumor Lysis Syndrome (see Appendix E). Subjects may be enrolled upon correction of electrolyte abnormalities.
  • Patients who require therapy with systemic corticosteroids.
  • Prior history of malignancy within the past five years or a concurrent malignancy, with the exceptions of cutaneous basal cell carcinoma or carcinoma in situ of the uterine cervix.
  • Pregnant or lactating women.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01180569

Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Celgene Corporation
Principal Investigator: Carol Portlock, MD Memorial Sloan Kettering Cancer Center
  More Information

Additional Information:
Responsible Party: Memorial Sloan Kettering Cancer Center Identifier: NCT01180569     History of Changes
Other Study ID Numbers: 10-022
Study First Received: August 10, 2010
Last Updated: September 24, 2015

Keywords provided by Memorial Sloan Kettering Cancer Center:

Additional relevant MeSH terms:
Lymphoma, Follicular
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Immunosuppressive Agents
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents processed this record on April 26, 2017